Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased?
Adolescent
Adult
Aged
Carboplatin
/ administration & dosage
Chemotherapy, Adjuvant
Combined Modality Therapy
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Humans
Late Onset Disorders
/ chemically induced
Male
Middle Aged
Neoplasm Staging
Neoplasms, Second Primary
/ epidemiology
Radiotherapy, Adjuvant
Retrospective Studies
Seminoma
/ drug therapy
Testicular Neoplasms
/ drug therapy
Treatment Outcome
Watchful Waiting
Young Adult
Carboplatin
Late toxicity
Radiotherapy
Second cancer
Seminoma
Surveillance
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
27
10
2018
accepted:
01
07
2019
pubmed:
10
7
2019
medline:
29
8
2019
entrez:
10
7
2019
Statut:
ppublish
Résumé
Clinical stage (CS) 1 testicular seminoma is cured in almost 100% of cases following either retroperitoneal radiotherapy, carboplatin monotherapy, or surveillance strategies. Little is known about potential long-term effects of carboplatin. We, therefore, examined late sequelae of this drug in seminoma patients. We retrospectively identified 451 patients with CS1 testicular seminoma treated between 1994 and 2014, of whom 243 underwent carboplatin therapy [median follow-up (F/U) 96 months], 81 received radiotherapy (median F/U 142 months), and 127 underwent surveillance (median F/U 40 months). Satisfaction regarding management, as well as the following events during F/U, were analysed by questionnaire: subsequent malignant neoplasms (SMNs), cardiovascular events, arterial hypertension, peptic ulcer, tinnitus, peripheral neuropathy, hypogonadism, and infertility. The relative frequencies of the events were analysed using descriptive statistics. The frequency of observed SMNs was compared with the expected number. Patients receiving carboplatin tolerated the treatment less well (71.2%) than those under surveillance (81.9%). After carboplatin, 12 SMNs (5.0%) were noted vis-a-vis 5.0 expected. There were three cases of prostatic cancer and 3 melanomas among the SMNs. Half of these SMNs occurred early after treatment. Among the other health events, only reported hypogonadism (13.2%) appeared to be marginally increased in frequency. This study found a 2.4-fold higher than expected rate of SMN-and a slightly increased rate of hypogonadism-in the long-term period following carboplatin treatment. Although further studies are needed to confirm these preliminary findings, these results are probably informative for clinicians caring for seminoma patients.
Identifiants
pubmed: 31286241
doi: 10.1007/s00432-019-02965-5
pii: 10.1007/s00432-019-02965-5
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2335-2342Commentaires et corrections
Type : CommentIn
Références
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068
doi: 10.1016/j.eururo.2015.07.044
pubmed: 26297604
Aparicio J, Maroto P, García del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR (2014) Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 25:2173–2178
doi: 10.1093/annonc/mdu437
pubmed: 25210015
Bandak M, Jørgensen N, Juul A, Vogelius IR, Lauritsen J, Kier MG, Mortensen MS, Glovinski P, Daugaard G (2016) Testosterone deficiency in testicular cancer survivors—a systematic review and meta-analysis. Andrology 4(3):382–388
doi: 10.1111/andr.12177
pubmed: 27009402
Berghen C, Albersen M, Blanchard P, Bossi A, Briganti A, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G (2019) Readressing the rationale of irradiation in Stage I seminoma guidelines: a critical essay. BJU Int 124(1):35–39
doi: 10.1111/bju.14686
pubmed: 30680874
Brown WM, Doll R (1965) Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 2(5474):1327–1332
doi: 10.1136/bmj.2.5474.1327
pubmed: 5848660
pmcid: 1846756
Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T (2015) Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ cell tumour: Results from a 17 year UK experience. Ann Oncol 26(9):1865–1870
doi: 10.1093/annonc/mdv254
pubmed: 26037797
Dieckmann K-P, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H (2000) Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55:102–106
doi: 10.1016/S0090-4295(99)00376-3
pubmed: 10654903
Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, Pichlmeier U (2016) Seminoma clinical stage 1—patterns of care in Germany. Urol Int 96(4):390–398
doi: 10.1159/000443214
pubmed: 27092560
Dieckmann KP, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, Pichlmeier U (2018) Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int 100(4):409–419
doi: 10.1159/000488284
pubmed: 29649815
pmcid: 6039091
Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a Population-Based Study. J Clin Oncol 31(30):3807–3814
doi: 10.1200/JCO.2013.50.3409
pubmed: 24043737
pmcid: 3795890
Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M (2018) Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol 36(24):2504–2513
doi: 10.1200/JCO.2017.77.4174
pubmed: 29989856
Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R (2011) Nachsorge von Patienten mit Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. [Follow-up of testicular germ cell cancer patients: Interdisciplinary evidence-based recommendations]. Urologe A 50(7):830–835
doi: 10.1007/s00120-011-2556-0
pubmed: 21503662
Hay JH, Duncan W, Kerr GR (1984) Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 57:597–602
doi: 10.1259/0007-1285-57-679-597
pubmed: 6539633
Horwich A, Alsanjari N, Hern RA, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65:775–778
doi: 10.1038/bjc.1992.164
pubmed: 1586607
pmcid: 1977398
Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256–263
doi: 10.1038/bjc.2013.551
pubmed: 24263066
Kier MG, Hansen MK, Lauritsen J, Mortensen MS, Bandak M, Agerbaek M, Holm NV, Dalton SO, Andersen KK, Johansen C, Daugaard G (2016) Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish Nationwide Cohort Study. JAMA Oncol 2(12):1624–1627
doi: 10.1001/jamaoncol.2016.3651
pubmed: 27711914
Lewinshtein D, Gulati R, Nelson PS, Porter CR (2012) Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 109(5):706–712
doi: 10.1111/j.1464-410X.2011.10424.x
pubmed: 21883828
Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase H, Daugaard G (2014) A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 66:1172–1178
doi: 10.1016/j.eururo.2014.07.001
pubmed: 25064686
Neuhauser H, Kuhnert R, Born S (2017) 12 Monats Prävalenz von Bluthochdruck in Deutschland. J Health Monitoring 2(1):57–63. https://doi.org/10.17886/RKI-GBE-2017-008
doi: 10.17886/RKI-GBE-2017-008
Nöst G, Lipsky H, Würnschimmel E (1998) Carboplatinmonotherapie im klinischen Stadium I des Seminoms. Eine akzeptable Alternative? Urologe A 37:629–634
doi: 10.1007/s001200050226
pubmed: 9887492
Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Tandstad T (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838
doi: 10.1093/annonc/mdu514
pubmed: 25378299
Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, Collaborators MTcatE (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300
doi: 10.1016/S0140-6736(05)66984-X
pubmed: 16039331
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962
doi: 10.1200/JCO.2009.26.4655
pubmed: 21282539
Patel HD, Srivastava A, Alam R, Joice GA, Schwen ZR, Semerjian A, Allaf ME, Pierorazio PM (2017) Radiotherapy for stage I and II testicular seminomas: secondary malignancies and survival. Urol Oncol 35:606.e1–606.e7
doi: 10.1016/j.urolonc.2017.06.051
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443–447
doi: 10.1093/annonc/mdm540
pubmed: 18048383
Pühse G, Secker A, Kemper S, Hertle L, Kliesch S (2011) Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl 34(5 Pt 2):e351–e357
doi: 10.1111/j.1365-2605.2010.01123.x
pubmed: 21062302
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C (2016) Testicular germ cell tumours. Lancet 387(10029):1762–1774
doi: 10.1016/S0140-6736(15)00991-5
pubmed: 26651223
Reiter WJ, Kratzik C, Brodowicz T, Haitel A, Pokorny A, Zielinski CC, Marberger M (1998) Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology 52:117–119
doi: 10.1016/S0090-4295(98)00139-3
pubmed: 9671881
Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nöst G, Lipsky H, Marberger M, Kratzik C (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101–104
doi: 10.1200/JCO.2001.19.1.101
pubmed: 11134201
Robert Koch Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland (2015) Krebs in Deutschland 2011/12, 10. Ausgabe. Robert Koch Institut, Berlin. https://doi.org/10.17886/rkipubl-2015-004
Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP (2014) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 32(1):33.e1–33.e6
doi: 10.1016/j.urolonc.2012.12.002
Steiner H, Scheiber K, Berger AP, Rein P, Hobisch A, Aufderklamm J, Pilloni S, Stoehr B, Aigner F, Fritzer A, Zangerl F (2011) Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int 107(7):1074–1079
doi: 10.1111/j.1464-410X.2010.09658.x
pubmed: 21438975
Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Partl R, Kapp KS, Stöger H, Gerger A, Stotz M (2017) Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol 9(11):1400–1408
doi: 10.1007/s12094-017-1742-y
Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JDJ, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365
doi: 10.1093/jnci/dji278
pubmed: 16174857
van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370–4378
doi: 10.1200/JCO.2006.10.5296
pubmed: 17906202
Zengerling F, Müller J, Schrader AJ, Schrader M (2013) Clinical stage I seminoma: is surveillance a new therapy standard? [Article in German]. Urologe A 52(9):1265–1269
doi: 10.1007/s00120-013-3319-x
pubmed: 23979446